J
João Dias-Ferreira
Researcher at University of Coimbra
Publications - 22
Citations - 516
João Dias-Ferreira is an academic researcher from University of Coimbra. The author has contributed to research in topics: Drug delivery & Cancer. The author has an hindex of 8, co-authored 21 publications receiving 260 citations. Previous affiliations of João Dias-Ferreira include University of Porto.
Papers
More filters
Journal ArticleDOI
Current Applications of Nanoemulsions in Cancer Therapeutics.
Elena Sánchez-López,Mariana Guerra,João Dias-Ferreira,Ana López-Machado,Miren Ettcheto,Miren Ettcheto,Amanda Cano,Marta Espina,Antoni Camins,Antoni Camins,Maria Luisa García,Eliana B. Souto,Eliana B. Souto +12 more
TL;DR: Nanoemulsions are pharmaceutical formulations composed of particles within a nanometer range that possess the capacity to encapsulate drugs that are poorly water soluble due to their hydrophobic core nature and are a stable and safe option to deliver drugs.
Journal ArticleDOI
Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents
Eliana B. Souto,Eliana B. Souto,João Dias-Ferreira,Ana López-Machado,Miren Ettcheto,Amanda Cano,Antonio Camins Espuny,Marta Espina,Maria Luisa García,Elena Sánchez-López +9 more
TL;DR: This review discusses the different types of advanced formulations used for ocular delivery of therapeutics presenting the most recent patents according to the clinical applications.
Journal ArticleDOI
Nanopharmaceutics: Part I-Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU.
Eliana B. Souto,Gabriela F. Silva,João Dias-Ferreira,Aleksandra Zielińska,FV Ventura,Alessandra Durazzo,Massimo Lucarini,Ettore Novellino,Antonello Santini +8 more
TL;DR: The available legislation on nanopharmaceuticals within the European Union (EU), the GMP that should be followed for their production, and the current challenges encountered in clinical trials of these new formulations are addressed.
Journal ArticleDOI
Nanopharmaceutics: Part II—Production Scales and Clinically Compliant Production Methods
Eliana B. Souto,Gabriela F. Silva,João Dias-Ferreira,Aleksandra Zielińska,FV Ventura,Alessandra Durazzo,Massimo Lucarini,Ettore Novellino,Antonello Santini +8 more
TL;DR: Regulatory issues concerning nanopharmaceutics still require expertise for harmonizing legislation and a clear understanding of clinically compliant production methods.
Journal ArticleDOI
Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems
Eliana B. Souto,João Dias-Ferreira,Jéssica Oliveira,Elena Sánchez-López,Elena Sánchez-López,Ana López-Machado,Ana López-Machado,Marta Espina,Maria Luisa García,Selma B. Souto,Carlos Martins-Gomes,Amélia M. Silva +11 more
TL;DR: The current classical pharmacotherapy of AD against new nanoparticle skin delivery systems and their toxicologic risks are discussed, including the use of topical corticosteroids as a first-line therapy.